CW October 2004
Volume 13Issue Number 10 October 2004 ISSN 10593802 Aromatase Gene Variant Predicts Letrozole ResponseAmong postmenopausal women with advanced breast cancer VERIFY, those with a common variant of the aromatase gene may be more likely to respond to treatment with the aromatase inhibitor letrozole (Femara, Novartis).
Go to Previous Page Go to Next Page Source & Additional Reading Ramon Colomer, presented at the 40th Annual Meeting of the American Society of Clinical Oncology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW October 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
